Drug Profile

IX 001

Alternative Names: IX-001; IX001 TCR-T Injection

Latest Information Update: 30 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ImmuXell Biotech
Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

27 Mar 2025 Phase-I clinical trials in Pancreatic cancer (Inoperable/Unresectable, Second-line therapy or greater, Metastatic disease, Late-stage disease) in China (IV-infusion) (CTR20251024) (NCT06898385)
09 Oct 2024 Preclinical trials in Pancreatic cancer in China (IV-infusion), prior to October 2024
09 Oct 2024 ImmuXell submits IND application for IX 001 in Pancreatic cancer in China, prior to October 2024

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com